Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: The large international predict study

Clinical Genitourinary Cancer

Volumn 13, Issue 2, 2015, Pages 156-164.e1

  Jager D ^a   Ma, J H ^b   Mardiak, J ^c   Ye, D W ^d   Korbenfeld, E ^e   Zemanova, M ^f   Ahn, H ^g   Guo, J ^h   Leonhartsberger, N ⁱ   Stauch, K ^j   Bockenhoff A ^j   Yu, J ^k   Escudier, B ^l  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CANCER HOSPITAL   (China)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^f CHARLES UNIVERSITY   (Czech Republic)

^g Asan Medical Center   (South Korea)

^h PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j BAYER PHARMA AG   (Germany)

^k BAYER CORPORATION   (United States)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Clinical practice; Multikinase inhibitor; Noninterventional study; Targeted agent; Tolerability

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; ALOPECIA; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; CONTROLLED STUDY; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PRURITUS; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; ETHNOLOGY; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924534433     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.07.007     Document Type: Article

References (35)

1. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
2. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
3. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
4. R.J. Motzer, D. Nosov, and T. Eisen Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial J Clin Oncol 31 2013 3791 3799
5. R.J. Motzer, C. Porta, and N.J. Vogelzang Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial Lancet Oncol 15 2014 286 296
6. T.E. Hutson, B. Escudier, and E. Esteban Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 2014 760 767
7. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
8. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
9. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
10. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
11. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
12. C.N. Sternberg, C. Szczylik, and E. Lee A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) J Clin Oncol 28 2010 1061 1068
13. N. Howlader, A.M. Noone, and M. Krapcho SEER Cancer Statistics Review, 1975-2008, National Cancer Institute 2011 SEER Cancer Statistics Review Bethesda, MD Available at: http://seer.cancer.gov/csr/1975-2008/index.html Accessed:25 October 2011
14. M.S. Aapro, C.H. Kohne, H.J. Cohen, and M. Extermann Never too old? Age should not be a barrier to enrollment in cancer clinical trials Oncologist 10 2005 198 204
15. D.Y. Heng, T.K. Choueiri, and B.I. Rini Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials Ann Oncol 25 2014 149 154
16. J. Beck, G. Procopio, and E. Bajetta Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings Ann Oncol 22 2011 1812 1823
17. R.M. Bukowski, W.M. Stadler, and D.F. McDermott Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program Oncology 78 2010 340 347
18. W.M. Stadler, R.A. Figlin, and D.F. McDermott Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280
19. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
20. M. Sun, S.F. Shariat, and C. Cheng Prognostic factors and predictive models in renal cell carcinoma: a contemporary review Eur Urol 60 2011 644 661
21. C. Bokemeyer, T. Eisen, and C. Szczylik Sorafenib (sor) dosage patterns in >4600 patients (pts) with renal cell carcinoma (RCC), including the elderly and pts treated for >12 months (mo): results from an integrated database of 8 company-sponsored trials Ann Oncol 21 suppl 8 2010 viii, 287 (abstract 916P)
22. E. Jonasch, P. Corn, and L.C. Pagliaro Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis Cancer 116 2010 57 65
23. G. Procopio, E. Verzoni, and S. Bracarda Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial Br J Cancer 104 2011 1256 1261
24. B.I. Rini, C. Szczylik, and N.M. Tannir AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study Cancer 118 2012 6152 6161
25. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
26. T.E. Hutson, R.M. Bukowski, C.L. Cowey, R. Figlin, B. Escudier, and C.N. Sternberg Sequential use of targeted agents in the treatment of renal cell carcinoma Crit Rev Oncol Hematol 77 2011 48 62
27. C. Porta, P. Procopio, and G. Cartenì Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 8 Pt 2 2011 E250 E257
28. G. Procopio, E. Verzoni, R. Iacovelli, V. Guadalupi, F. Gelsomino, and R. Buzzoni Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience Expert Rev Anticancer Ther 11 2011 1631 1640
29. M.S. Michel, W. Vervenne, and M. De Santis SWITCH: a randomized, sequential, open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC) J Clin Oncol 32 suppl 4 2014 abstract 393
30. R.J. Motzer, B. Escudier, and P. Tomczak Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 2013 552 562
31. T.E. Hutson, V. Lesovoy, and S. Al-Shukri Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Lancet Oncol 14 2013 1287 1294
32. G. Procopio, J. Bellmunt, and J. Dutcher Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis Br J Cancer 108 2013 311 318
33. K. Edmonds, D. Hull, and A. Spencer-Shaw Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group Eur J Oncol Nurs 16 2012 172 184
34. T. Eisen, C.N. Sternberg, and C. Robert Targeted therapies for renal cell carcinoma: review of adverse event management strategies J Natl Cancer Inst 104 2012 93 113
35. M.E. Lacouture, S. Wu, and C. Robert Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 2008 1001 1011